Rapastinel belongs to a group of compounds, referred to as ''[[glyxin]]s'' (hence the original developmental code name of rapastinel, GLYX-13),<ref name="BurgdorfZhang2011">{{cite journal|last1=Burgdorf|first1=Jeffrey|last2=Zhang|first2=Xiao-lei|last3=Weiss|first3=Craig|last4=Matthews|first4=Elizabeth|last5=Disterhoft|first5=John F.|last6=Stanton|first6=Patric K.|last7=Moskal|first7=Joseph R.|title=The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats|journal=Neurobiology of Aging|volume=32|issue=4|year=2011|pages=698–706|issn=0197-4580|doi=10.1016/j.neurobiolaging.2009.04.012|pmid=19446371|pmc=3035742}}</ref> that were derived via [[structural modification]] of [[B6B21]], a [[monoclonal antibody]] that similarly binds to and modulates the NMDA receptor.<ref name="pmid26997507" /><ref name="pmid1828831">{{cite journal | vauthors = Haring R, Stanton PK, Scheideler MA, Moskal JR | title = Glycine-like modulation of N-methyl-D-aspartate receptors by a monoclonal antibody that enhances long-term potentiation | journal = J. Neurochem. | volume = 57 | issue = 1 | pages = 323–32 | year = 1991 | pmid = 1828831 | doi = 10.1111/j.1471-4159.1991.tb02131.x| url = }}</ref><ref name="pmid16051282">{{cite journal | vauthors = Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S, Harris RB, Disterhoft JF | title = GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator | journal = Neuropharmacology | volume = 49 | issue = 7 | pages = 1077–87 | year = 2005 | pmid = 16051282 | doi = 10.1016/j.neuropharm.2005.06.006 | url = }}</ref> The glyxins were invented by Joseph Moskal, the co-founder of Naurex.<ref name="BurgdorfZhang2011" /> Glyxins and B6B21 do not bind to the glycine site of the NMDA receptor but rather to a different regulatory site on the NMDA receptor complex that serves to allosterically modulate the glycine site.<ref name="pmid26830963">{{cite journal|year=2016|title=NMDA Receptor Glycine Site Modulators as Therapeutics for Depression: Rapastinel has Antidepressant Activity without Causing Psychotomimetic Side Effects|url=|journal=Curr Neuropharmacol|volume=|issue=|pages=|doi=|pmid=26830963|vauthors=Burch RM, Amin Khan M, Houck D, Yu W, Burgdorf J, Moskal JR}}</ref> As such, rapastinel is technically an [[allosteric modulator]] of the glycine site of the NMDA receptor, and hence is more accurately described as a ''functional'' glycine site weak partial agonist.<ref name="pmid26830963" />

 
In addition to its antidepressant effects, rapastinel has been shown to [[nootropic|enhance memory and learning]] in both young adult and [[learning impairment|learning-impaired]], aging [[animal model|rat model]]s.<ref>{{cite journal |doi=10.1016/j.neurobiolaging.2009.04.012 |title=The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats |year=2011 |last1=Burgdorf |first1=Jeffrey |last2=Zhang |first2=Xiao-lei |last3=Weiss |first3=Craig |last4=Matthews |first4=Elizabeth |last5=Disterhoft |first5=John F. |last6=Stanton |first6=Patric K. |last7=Moskal |first7=Joseph R. |journal=Neurobiology of Aging |volume=32 |issue=4 |pages=698–706 |pmid=19446371 |pmc=3035742}}</ref> It has been shown to increase [[Schaffer collateral]]-[[Cornu Ammonis area 1|CA1]] [[long-term potentiation]] ''[[in vitro]]''. In concert with a learning task, rapastinel has also been shown to elevate [[gene expression]] of [[hippocampus|hippocampal]] [[GRIN1|NR1]], a subunit of the NMDA receptor, in three-month-old rats.<ref>{{cite journal |doi=10.1016/j.neuropharm.2005.06.006 |title=GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-d-aspartate receptor modulator |year=2005 |last1=Moskal |first1=Joseph R. |last2=Kuo |first2=Amy G. |last3=Weiss |first3=Craig |last4=Wood |first4=Paul L. |last5=O'Connor Hanson |first5=Amy |last6=Kelso |first6=Stephen |last7=Harris |first7=Robert B. |last8=Disterhoft |first8=John F. |journal=Neuropharmacology |volume=49 |issue=7 |pages=1077–87 |pmid=16051282}}</ref> [[Neuroprotective]] effects have also been demonstrated in [[Mongolian Gerbils]] by delaying the death of CA1, [[Cornu Ammonis area 3|CA3]], and [[dentate gyrus]] [[pyramidal neurons]] under glucose and oxygen-deprived conditions.<ref>{{cite journal |doi=10.1097/WNR.0b013e32832f5130 |title=Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13 |year=2009 |last1=Stanton |first1=Patric K. |last2=Potter |first2=Pamela E. |last3=Aguilar |first3=Jennifer |last4=Decandia |first4=Maria |last5=Moskal |first5=Joseph R. |journal=NeuroReport |volume=20 |issue=13 |pages=1193–7 |pmid=19623090}}</ref> Additionally, rapastinel has demonstrated [[antinociception|antinociceptive]] activity, which is of particular interest, as both competitive and noncompetitive [[NMDA receptor antagonist]]s are [[ataxic]] at [[analgesic]] doses, while rapastinel and other glycine subunit [[ligand (biochemistry)|ligands]] are able to elicit analgesia at non-ataxic doses.<ref>{{cite journal |doi=10.1097/WNR.0b013e32830435c9 |title=Antinociceptive action of GLYX-13: An N-methyl-D-aspartate receptor glycine site partial agonist |year=2008 |last1=Wood |first1=Paul L. |last2=Mahmood |first2=Siddique A. |last3=Moskal |first3=Joseph R. |journal=NeuroReport |volume=19 |issue=10 |pages=1059–61 |pmid=18580579}}</ref>
